Corcept names Roberto Vieira as President, Oncology in initial beneficial ownership filing
CORT•Initial beneficial ownership filing for new oncology president
- Corcept Therapeutics President, Oncology Roberto Wandenkolk Vieira disclosed 4,068 common shares in an initial SEC Form 3 filing.
- Filing also reports stock options covering 480,000 shares, including 200,000 at $21.63.
